CAR T-cells for the treatment of bone metastatic cancer
US12156888B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2019 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Feb 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen, such as a prostate antigen for bone metastatic prostate cancer, or a breast cancer antigen for bone metastatic breast cancer. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.